Cue Biopharma Reports Positive Interim Phase I Data for Drug Candidate CUE-101
02:51 PM EDT, 05/10/2021 (MT Newswires) -- Cue Biopharma (CUE) said that interim data from a Phase I clinical study showed a partial response in a patient to its drug candidate CUE-101.
Cue is testing CUE-101 as a monotherapy for patients with HPV+ recurrent/metastatic head and neck squamous cell carcinoma.
The company also reported stable disease in several patients.
"We are very excited by the partial response observed in this patient, since it demonstrates single-agent activity of CUE-101, so rarely seen in mono-immunotherapy treatments," said Ken Pienta, acting chief medical officer of Cue Biopharma, in a statement. "This provides evidence that CUE-101 is an active agent with promising potential for HPV+ HNSCC patients."
Price: 14.84, Change: +3.58, Percent Change: +31.79